ImmunityBio Approves 2025 Equity Incentive Plan

An update from ImmunityBio ( (IBRX) ) is now available.

On June 18, 2025, ImmunityBio, Inc. held its Annual Meeting of Stockholders, where the 2025 Equity Incentive Plan was approved, replacing the 2015 Plan. This strategic move aims to better compete for and motivate key talent through equity-based awards, aligning the interests of employees and stockholders. Additionally, eight directors were re-elected, and Deloitte & Touche LLP’s appointment as the independent registered public accounting firm for 2025 was ratified.

The most recent analyst rating on (IBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.

Spark’s Take on IBRX Stock

According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.

ImmunityBio’s overall stock score is primarily impacted by its weak financial performance, characterized by high leverage, persistent losses, and negative cash flows. The technical analysis provides a neutral outlook with no strong momentum signals. Valuation remains a concern due to unprofitability. However, the recent financing event is a positive factor, enhancing liquidity and supporting strategic initiatives.

To see Spark’s full report on IBRX stock, click here.

More about ImmunityBio

ImmunityBio, Inc. operates in the biotechnology industry, focusing on developing innovative immunotherapy products. The company aims to enhance immune system responses to treat cancer and infectious diseases, with a market focus on leveraging equity-based incentives to attract and retain key talent.

Average Trading Volume: 9,386,534

Technical Sentiment Signal: Sell

Current Market Cap: $2.51B

Learn more about IBRX stock on TipRanks’ Stock Analysis page.